Ming Bai

Mar 5, 2024 | bmccancer.biomedcentral.com | Jingjing Duan |Yinghui Shi |weixue Wang |Tongtong Wang |Tao Ning |Le Fu Zhang | +8 more

Between January 2013 and December 2020, 183 patients with mCRC who met the inclusion and exclusion criteria from the Tianjin Medical University Cancer Institute and Hospital were selected. Among them, 143 patients received chemotherapy ± targeted drugs, and the remaining 40 patients were given anti-angiogenic monotherapy. The baseline disease characteristics at the index date of third-line therapy were listed in Table 1.

Feb 22, 2024 | bmccancer.biomedcentral.com | Yuchong Yang |Hui Tan |Yao Lu |Mengqi Zhang |Ming Bai |Xia Wang | +9 more

Until now, controversy still exists on the optimal cut-off values of NLR, PLR and fibrinogen for predicting prognosis in ESCC. In our study, we use the method of c-index to determine the optimal cut-off values of these biomarkers. The results showed that the c-index values were maximum for OS (and/or DFS) when NLR, PLR and fibrinogen were 1.6, 126, and 3.8, respectively (Table S1).